GlassScriptPhysician profile
Alexander George
NPI 1124552559
$938.79
in general payments reported to CMS, 2019-2025
16 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $109 · 2024: $313 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266.48 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $112.42 | 2023-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.27 | 2024-2025 | Xifaxan |
| Corcept Therapeutics | $83.50 | 2024-2025 | Korlym |
| Abbvie INC. | $67.16 | 2024-2025 | |
| Amgen INC. | $64.39 | 2024-2025 | Repatha, Otezla, Evenity |
| Shield Therapeutics INC | $56.68 | 2023-2025 | Accrufer |
| Hologic Sales and Service, LLC | $36.98 | 2024-2025 | Aptima |
| Viatris Specialty LLC | $29.53 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.19 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $19.76 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $18.17 | 2023 | Gvoke Hypopen |
| Biogen, INC. | $17.01 | 2025 | Skyclarys |
| Glaxosmithkline, LLC. | $15.42 | 2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $13.03 | 2023 | Airsupra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $12.80 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.